Differences in the outcome variable could explain the fact that we did not replicate previous results. The literature has shown that cannabinoid receptors are involved in neurodevelopment, brain maturation, and could also be involved in psychosis and addiction. By studying the psychotomimetic effects at initiation of cannabis use (i.e. at 15.9 ± 1.8 years of age) in healthy young students with no psychosis or addiction, our study focused on the influence of CNR1 gene variants in the expression of psychosis through the role of CNR1 in the brain maturation occurring during adolescence. In these young students, the association of CNR1 variants with psychotomimetic effects induced by cannabis at first use could accurately reflect the genetic risk of psychosis when exposed to cannabis, by avoiding the confounding factors of preexisting psychosis or the association of these genetic variants to psychosis or addiction. Our results should be replicated in representative samples of the general population. In addition, the predictive value of this genetic marker for developing psychotic disorders when exposed to cannabis has to be determined in prospective studies in the general population as well as in individuals who are at risk for psychosis.
Clozapine is a prototypical atypical antipsychotic drug. Its primary indication is for treatment-resistant schizophrenia and reduction of the risk for suicide. 1 In spite of its efficacy, the use of clozapine is markedly curtailed by its side effects such as metabolic syndrome and agranulocytosis. 2 Although metabolic syndrome is more common than agranulocytosis, it is the latter which is the major reason that clinicians and patients are reluctant to consider the use of clozapine. Clozapine-induced agranulocytosis (CIA) occurs in about 0.8% of clozapine-treated patients, generally within the first 18 weeks of treatment and is characterized by a decrease in absolute neutrophil count (ANC) below 500 cells mm −3 . The etiologic mechanism of CIA is unknown although several hypotheses have been proposed. These include nitrenium ion-mediated apoptosis, mitochondrial oxidative stressinduced apoptosis or direct cytotoxicity against mesenchymal stromal cells in the bone marrow. In addition, an immunemediated toxicity mechanism, based on reoccurrence of agranulocytosis within several days of reexposure to clozapine in patients who have had agranulocytosis, is considered to be a likely cause (reviewed in Chowdhury et al. 2 and Opgen-Rhein and Dettling
3
). Among the demographic risk factors for agranulocytosis are increased age and Asian or Finnish ancestry. Concordance of agranulocytosis has been reported in monozygotic twins and genetic polymorphisms, for example, in the major histocompatibility complex (HLA) genes (e.g. HLAB38 4 and HLA-DQB1 (6,672G>C) 5 ) have been associated with CIA (reviewed in Chowdhury et al. 2 and Opgen-Rhein and Dettling
). In this study, we have utilized exome sequencing to comprehensively identify the genetic variation in the transcribed region of the genome in Finnish patients with and without CIA. Considering that CIA is rare, it is likely that low-frequency variants may also contribute to its development.
Schizophrenia or schizoaffective disorder patients (n = 50) diagnosed according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria were included in the study. Informed consent and approval by institutional ethics review board were obtained. Cases (n = 24) were diagnosed to be suffering from severe neutropenia (threatening agranulocytosis) based on the observation of a rapid decline in the ANC to o 1,500 cells mm −3 . Of these 24 patients, 13 developed a definite agranulocytosis (ANC ⩽ 500 cells mm −3 ) despite immediate discontinuation of clozapine. Controls were matched for age and sex and came from the same region of Finland as the cases. The distribution of age, gender and clozapine dose was not significantly different between cases and controls (Supplementary Table 1 ).
The enrichment of targeted regions (consensus coding sequence definition of exons and flanking introns, ∼ 50 Mb) was carried out using the Agilent SureSelect Human All Exon 50 Mb Kit (Agilent Technologies, Santa Clara, CA, USA) and the sequencing was carried out using the Illumina HiSeq 2,000 platform (Illumina, San Diego, CA, USA Table 2 Table 1 . This is the first study analyzing the whole exome sequence of schizophrenia patients suffering from CIA. The sample size for the current study is relatively small but has an important advantage of using a genetically homogeneous patient population of Finnish ancestry. The lack of significant association suggests that the genetic etiology is complex (for example, locus or allelic heterogeneity, incomplete penetrance and epistasis), or that genetic variants that are not captured well by exome sequencing are responsible for CIA.
Among the top genes nominally associated with CIA (Table 1) , PPFIA4 (protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), α4) is a member of the liprin-α family of proteins and interacts with the leukocyte common antigen-related receptor protein tyrosine phosphatase F. Recent studies have shown that PPFIA4 has a role in maintaining cell-cell adhesion and its expression is increased following exposure to hypoxia and nickel. 6, 7 The protein binds to the cytoplasmic region of PTPRF, increasing the phosphatase activity and preventing nickel-induced toxicity. The function of rs2270540 is unknown but it is present in a conserved region and is in high correlation with another conserved SNP rs903365, which is in a potential weak promoter/enhancer region.
The second hit was in the ubiquitin-specific peptidase 4 (USP43). Based on homology, it is predicted to have a role in processing poly-ubiquitin precursors and ubiquitinated proteins, and to interact with the 14-3-3 family of proteins. 8 The latter are highly conserved proteins that are involved in the control of cell cycle, cell growth, differentiation, survival and apoptosis among other functions. 9 The SNP rs12450515 associated with CIA in this study is a conserved, synonymous amino acid change that alters transcription factor binding and is present in the vicinity of an insulator element.
A third SNP of interest (rs3742897) is located in an intronic region of ACTN1 (actinin-α-1). This gene is expressed throughout the body including monocytes, neutrophils and T lymphocytes. α-Actinins are cytoskeletal proteins that belong to filamentous actin crosslinking protein superfamily. Importantly, α-actinin-1 has been shown to have an important role in T-cell migration, a necessary process in adaptive immune response, 10 and T-cell activation and formation of immune and viral 'synapses'. 11 In addition, the α-actinins have been shown to be important target autoantigens in autoimmune diseases such as systemic lupus erythematosus and autoimmune hepatitis type-1. 10 It is possible that a similar aberrant T-cell migration and/or autoimmune response may be occurring in patients with CIA.
The functions of PODNL1 (podocan-like protein 1) and SPATS1 (spermatogenesis-associated serine-rich 1) have not been determined.
It is important to note that these results did not reach studywide significance, and the associations have not been replicated in independent samples. Further analysis of the above-mentioned genes, especially ACTN1, may elucidate their role, if any, in CIA susceptibility.
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JLK has been a consultant to GSK, Sanofi-Aventis and Dainippon-Sumitomo. HYM has received grants, or payment for lectures, or is or was a consultant to: Abbott Labs, ACADIA, Alkemes, Bristol Myers Squibb, DaiNippon Sumitomo, Eli Lilly, EnVivo, Janssen, Otsuka, Pfizer, Novartis, Roche, Sunovion, TEVA and BiolineRx. HYM is a shareholder of ACADIA, Glaxo Smith Kline and Suregene. HYM is a board member of Acadia, and is an advisor to Centerstone Research Institute. JT is a member of advisory board of AstraZeneca and Janssen-Cilag, and reports serving as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, and lecture fees from Janssen-Cilag, Bristol MyersSquibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, Novartis, and Astra Zeneca. AKT/ ACN/FWL/CCZ/NIC/DJM/AP/ERT/AEAY declare no conflict of interest. A classifier was recently reported to predict with 70% accuracy if an individual has an autism spectrum disorder using 237 singlenucleotide polymorphisms (SNPs). 1 Biomarkers, genetic or otherwise, that would facilitate earlier autism spectrum disorder diagnosis are crucial; therefore, these results warrant careful scrutiny. One potential confounder of such genetic studies is bias when cases and controls have different ancestral origins. Here, we show that the largest components of this classifier's autism risk score distinguish populations, but do not separate cases from controls. In short, the frequencies of reported risk and protective alleles do not differ between related individuals with or without autism in independent data sets; instead, they reflect ancestral origin. Specifically, cases have more diverse ancestral origins within Europe than controls. The putative risk alleles are more common in the Northeastern than in the Northwestern Europe, whereas the putative protective alleles reflect the opposite trend. Likewise, we find that the autism risk scores based on the strongest SNPs do not differ between people with and without autism in an independent data set, but that they do differ between European populations.
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The classifier was originally trained using case-genotype data from the Autism Genetics Resource Exchange (AGRE). 2, 3 Although only the top 15 'risk' SNPs and the top 15 'protective' SNPs were provided, 1 even those 30 SNPs were reportedly sufficient for 58% accurate discrimination between controls (the Western and Northern European CEU population in HapMap3) and cases (the CEU-like AGRE cases). We thus applied the autism risk classifier to 379 cases and 472 related controls that had been added to AGRE after development of the classifier. Of the 30 SNPs comprising the classifier, 19 were genotyped in the new cohort. To match the original publication, we limited analysis to the individuals more similar to CEU than to any other HapMap3 population. The resulting distributions of autism risk scores were not significantly different between cases and controls (Figure 1 ; two-sided twosample Kolmogorov-Smirnov (K-S) test, P = 0.68). Likewise, we found no differences in the minor allele frequencies of any of the 30 putatively discriminative SNPs, neither at the level of an individual SNP (Fisher's exact test) nor when the P-value distributions were considered (K-S test). Furthermore, we found no difference between cases and controls in the same minor allele frequency comparisons within the Simons simplex collection (http://sfari.org/sfari-initiatives/simons-simplex-collection).
We then asked if the cases and controls have different ancestral origins. If so, population structure would be correlated with autism in the sample, leading to the faulty conclusion that genetic variants that differentiate populations instead mediate autism risk. Much of the genetic diversity among Europeans reflects geography. 4 To attempt to control for population structure, the classifier's authors excluded individuals whose genomes betterreflected HapMap3 populations other than CEU (a Western and Northern European population). For example, because an Italian population (TSI) was included in HapMap3, their removal reduced bias that could be introduced from different Northern and Southern origins in cases and controls within Europe. In both training and validation sets, the cases were European Americans who have diverse ancestral origins, whereas the controls were explicitly intended to represent populations in Northwestern Europe (CEU and a British birth cohort). This raised the concern that genetic differences between Eastern and Western Europeans could be a major confound.
To investigate this possibility, we compared the allele frequencies of the reported discriminative SNPs between CEU, 5 representing Northwestern Europe, and Estonians, 6 reflective of Northeastern Europe. Eighteen of the thirty SNPs were genotyped in both of these studies. Of these, all but one 'risk' SNP and one 'protective' SNP differed in the direction one would expect if the allele frequency distributions were due to population structure (Supplementary Table S1 ). The differences were striking: the mean and median odds ratios were 1.49 and 1.38 for Estonians and 0.66 and 0.69 for CEU (P = 3 × 10 −4 , 2-tailed t-test on the odds ratios), respectively.
To more directly confirm that cases and controls were taken from different populations, we plotted the two case sets and the training control set on the geographical axes of genetic variation in Europe (Figure 1; 4 ). As expected, cases had more diverse ancestral origins than controls. Whereas we did not have immediate access to the validation control set, it is a 1958 British birth cohort that is by definition Northwestern European. Therefore, although all of the SNPs in the classifier are not publicly available, the properties of the SNPs that are provided are most consistent with confounding due to population substructure. It was previously noted that the classifier was useless for individuals clustered with the Chinese population, 1 as one would expect if it were a spurious artifact of local European population structure. Further, the classifier was considerably less accurate for individuals clustering with the Italian HapMap group. 1 The poor performance among Southern Europeans may reflect differences between the East-West genetic gradients across Southern Europe and Northern
